



Simoa® Technology

Measure biomarkers at lower levels than ever before.

From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs made only possible through its unparalleled sensitivity and flexibility. The Single Molecule Array (Simoa®) technology has set the gold standard for earlier and ultrasensitive biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than conventional methods. Our industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator Lab have supported research that advances disease understanding, treatment and management in neurology, oncology, immunology, cardiology, and infectious disease.

Fueling cancer research with ultrasensitivity.

Quanterix has developed an ultrasensitive Simoa® platform capable of measuring individual proteins at concentrations several log-fold lower than conventional immunoassays. Simoa® technology enables the detection and quantification of biomarkers previously difficult or impossible to measure, opening new applications to address significant unmet needs in life science research and cancer biomarker detection. Simoa® assays have the potential to be used to identify early stage cancers, assess therapeutic outcome, and monitor minimal residual disease and potential cancer recurrence. Finally, Simoa® technology and platforms have been designed with flexibility in mind to enable the discovery and validation of novel cancer-relevant biomarkers. Furthermore, ultrasensitive custom assays have been successfully developed on Simoa® for applications ranging from detection of tumor derived extracellular vesicles, studying the PK/PD of anti-tumorigenic drugs, and predicting treatment response and survival outcome.

The HD-X™ and SR-X™ Bead-based Instruments

A menu of transferable assay kits between our bead-based instruments are available to researchers to measure critical biomarkers with higher sensitivity than standard immunoassay methods, enabling the detection of the target biomarker levels with high precision across a range of sample types.

HD-X ANALYZER™

Delivering Ultra-sensitive Biomarker Measurement You Can Count On.

Our latest HD-X model is a fully automated, high throughput, Simoa® bead-based immunoassay platform. HD-X delivers major productivity improvements, greater user flexibility, unparalleled sensitivity, and best-in-class assay performance across a broad assay menu to empower biomarker research and accelerate drug development.



SR-X™ BIOMARKER DETECTION SYSTEM

Access ultra-sensitive bead based technology in a compact benchtop system.



The Quanterix SR-X® Ultrasensitive Biomarker Detection System is the latest benchtop instrument from Quanterix powered by Simoa® technology, offering researchers access to ultra-sensitive protein detection capabilities in a compact and affordable system with increased workflow flexibility. The SR-X is designed to support multiplexed detection of up to four biomarkers per sample, with low sample volume requirements to increase throughput and productivity while conserving precious specimens.

The SP-X Planar Array Instrument

Ultrasensitive Imaging and Analysis System™

Unleashing the power of next generation Simoa® planar array technology for robust multiplex biomarker detection at the earliest stages of disease progression – even before recognizable symptoms begin.

The Simoa® planar immunoassay technology is a revolutionary new digital biomarker solution, with features that provide researchers an incredibly simple, flexible, robust, and sensitive multiplexing platform. The Quanterix SP-X™ Imaging and Analysis System is a complete benchtop system that offers true multiplex detection at both acute and baseline levels in serum and plasma. Now oncology and immuno-oncology researchers and others who rely on multiplexing capabilities have an easy-to-use platform to help optimize workflows, speed up their research, and ultimately accelerate drug approvals.

